|
|
|
|
 |
Volume 4, Issue 3 (Autumn 2026 2026) |
 |
|
|
|
|
Temporal Trends in Tuberculosis Prevalence and Burden in Iran, 1992–2022: A 30-Year Analysis
|
Yaser Sarikhani *1    , Aida Nankalipour2 |
1- Social Determinant of Health Research Center, Jahrom University of Medical Sciences, Jahrom, Iran. & Iranian Research Network for Social Determinants of Health (IRNSDH), Tehran, Iran., Research Center for Social Determinants of Health, Jahrom University of Medical Sciences, Jahrom, Iran. , yasersarikhani@yahoo.com
2- Student Research Committee, Jahrom University of Medical Sciences, Jahrom, Iran., Student Research Committee, Jahrom University of Medical Sciences, Jahrom, Iran. |
|
|
Abstract: (45 Views) |
Background: Tuberculosis (TB) remains one of the most significant public health challenges, and monitoring its long-term trends is essential for evaluating the effectiveness of disease control programs. This study aimed to assess the 30-year trend of TB prevalence and disease burden in Iran from 1994 to 2023.
Methods: This ecological descriptive study was conducted using data from the Global Burden of Disease study. Indicators of TB prevalence and disability-adjusted life years (DALYs) in Iran, the Eastern Mediterranean Region, and globally were extracted and analyzed as age-standardized rates per 100,000 population. Temporal trends were assessed using the Joinpoint regression model and the average annual percent change (AAPC), with a significance level set at 0.05.
Results: The findings indicated a decreasing trend in both DALYs and TB prevalence, with AAPCs of −4.50 and −0.39, respectively (P <0.001). In subgroups, both DALYs and prevalence of drug-susceptible TB showed declining trends, whereas multidrug-resistant TB and extensively drug-resistant TB demonstrated increasing trends (P <0.001).
Conclusion: Although the overall burden of TB in Iran has declined over the past three decades, the rising trend of drug-resistant forms highlights the continued need for strengthened early detection, surveillance of drug resistance, and targeted treatment strategies.
Keywords: Disability-adjusted life years, Global Burden of Disease, Prevalence, Tuberculosis, Iran
Acknowledgments: The authors would like to express their gratitude to the Vice-Chancellor for Research and Technology at Jahrom University of Medical Sciences for their intellectual and administrative support.
Conflict of Interest: The authors declare that they have no conflicts of interest regarding the conduct of this study.
Availability of Data and Materials: The data used in this study are publicly available through the Global Burden of Disease (GBD) database.
Consent for Publication: Not applicable.
Ethics Approval and Consent to Participate: This study was conducted in accordance with the principles of the Declaration of Helsinki. The research protocol was approved by the Ethics Committee of Jahrom University of Medical Sciences (Approval Code: IR.JUMS.REC.1403.109).
Financial Disclosure: The authors declare that they did not receive any financial support from any institution for the conduct of this study.
Author Contributions: Both authors contributed equally to all stages of the study and to the writing of the manuscript. |
|
| Keywords: Disability-adjusted life years, Global Burden of Disease, Prevalence, Tuberculosis, Iran |
|
|
Full-Text [PDF 1496 kb]
(1 Downloads)
|
|
Type of Study: Original |
Subject:
General
|
|
|
|
|
|
|
| References |
|
1. WHO. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: World Health Organization; 2014. 2. koohgard giulani R, ghasemi A. Factors Associated with Delayed Diagnosis of Tuberculosis in Patients Referred to Razi Hospital in Rasht, 2023. Iran J Health Res Dev 2026; 4 (1) :24-33. [ DOI:10.66224/jhrd.4.1.24] 3. Huang K, Hu C-Y, Yang X-Y, Zhang Y, Wang X-Q, Zhang K-D, et al. Contributions of ambient temperature and relative humidity to the risk of tuberculosis admissions: a multicity study in Central China. Science of the Total Environment. 2022;838:156272. [ DOI:10.1016/j.scitotenv.2022.156272] [ PMID] 4. Khurana AK, Aggarwal D. The (in) significance of TB and COVID-19 co-infection. European Respiratory Journal. 2020;56(2):2002105. [ DOI:10.1183/13993003.02105-2020] [ PMID] [ PMCID] 5. Visca D, Ong C, Tiberi S, Centis R, D'ambrosio L, Chen B, et al. Tuberculosis and COVID-19 interaction: a review of biological, clinical and public health effects. Pulmonology. 2021;27(2):151-65. [ DOI:10.1016/j.pulmoe.2020.12.012] [ PMID] 6. Menzies NA, Quaife M, Allwood BW, Byrne AL, Coussens AK, Harries AD, et al. Lifetime burden of disease due to incident tuberculosis: a global reappraisal including post-tuberculosis sequelae. The Lancet Global Health. 2021;9(12):e1679-e87. [ DOI:10.1016/S2214-109X(21)00367-3] [ PMID] [ PMCID] 7. Bagcchi S. WHO's global tuberculosis report 2022. The Lancet Microbe. 2023;4(1):e20. [ DOI:10.1016/S2666-5247(22)00359-7] [ PMID] 8. Ledesma JR, Ma J, Zhang M, Basting AV, Chu HT, Vongpradith A, et al. Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021. The Lancet infectious diseases. 2024;24(7):698-725. [ DOI:10.1016/S1473-3099(24)00007-0] [ PMID] [ PMCID] 9. Murray CJ. Findings from the global burden of disease study 2021. The Lancet. 2024;403(10440):2259-62. [ DOI:10.1016/S0140-6736(24)00769-4] [ PMID] 10. Mathers CD, Vos T, Lopez AD, Salomon J, Ezzati M. National burden of disease studies: a practical guide. Geneva: World Health Organization. 2001. 11. Kyu HH, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet. 2018;392(10159):1859-922. [ DOI:10.1016/S0140-6736(18)32335-3] [ PMID] 12. Allwood BW, Van Der Zalm M, Amaral A, Byrne A, Datta S, Egere U, et al. Post-tuberculosis lung health: perspectives from the First International Symposium. The International Journal of Tuberculosis and Lung Disease. 2020;24(8):820-8. [ DOI:10.5588/ijtld.20.0067] [ PMID] 13. Collaborators GCRD. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. The Lancet Respiratory Medicine. 2017;5(9):691. [ DOI:10.1016/S2213-2600(17)30293-X] [ PMID] 14. Bostani M, Dehghani M, Taghipour A, Raufi F, Bostani B. Adherence of Physicians to the National Tuberculosis Control Program (DOTS Strategy) and associated factors in Birjand City. Iran J Health Res Dev 2026; 4 (2) :94-106 [ DOI:10.66224/jhrd.4.2.94] 15. Meghji J, Gregorius S, Madan J, Chitimbe F, Thomson R, Rylance J, et al. The long term effect of pulmonary tuberculosis on income and employment in a low income, urban setting. Thorax. 2021;76(4):387-95. [ DOI:10.1136/thoraxjnl-2020-215338] [ PMID] [ PMCID] 16. Duong M, Islam S, Rangarajan S, Leong D, Kurmi O, Teo K, et al. Mortality and cardiovascular and respiratory morbidity in individuals with impaired FEV1 (PURE): an international, community-based cohort study. The Lancet Global Health. 2019;7(5):e613-e23. [ DOI:10.1016/S2214-109X(19)30070-1] [ PMID] 17. Uplekar M, Weil D, Lonnroth K, Jaramillo E, Lienhardt C, Dias HM, et al. WHO's new end TB strategy. The Lancet. 2015;385(9979):1799-801. [ DOI:10.1016/S0140-6736(15)60570-0] [ PMID] 18. Lange C, Chesov D, Heyckendorf J, Leung CC, Udwadia Z, Dheda K. Drug‐resistant tuberculosis: an update on disease burden, diagnosis and treatment. Respirology. 2018;23(7):656-73. [ DOI:10.1111/resp.13304] [ PMID] 19. Li X, Li Y, Guo L, Chen Y, Wang G, Zhang H. Tuberculosis incidence, deaths and disability-adjusted life years in children and adolescence, 1990-2021: Results from the Global Burden of Disease Study 2021. PloS one. 2025;20(3):e0317880. [ DOI:10.1371/journal.pone.0317880] [ PMID] [ PMCID] 20. Cui K, Zhao X, Liu W, Bai L. Global, regional, and national burden and trends of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis in adolescents and adults aged 15-49 years from 2010 to 2021: insights from the global burden of disease study 2021. BMC medicine. 2025;23(1):445. [ DOI:10.1186/s12916-025-04269-7] [ PMID] [ PMCID] 21. Kaffash A, Shobeiri SS, Pouraslan E, Kazemzadeh A, Mohammadi FD, Ghazal N, et al. The epidemiology of tuberculosis infection and the Human Development Index (HDI) in Iran between 1990-2021: secondary analysis of the global burden of disease. BMC Infectious Diseases. 2026;26(1):995. [ DOI:10.1186/s12879-026-13148-2] [ PMID] [ PMCID] 22. Baghdadi S. Situational analysis of tuberculosis control programs in the Eastern Mediterranean Region: Gaps and solutions. International Journal of Mycobacteriology. 2016;5:S14. [ DOI:10.1016/j.ijmyco.2016.10.002] [ PMID] 23. Yuanyuan L, Jingjing X, Shutao L, Dongdong S, Tian Z, Puxuan L, et al. 2024 WHO tuberculosis report: key data analysis for China and the global world. Electronic Journal of Emerging Infectious Diseases. 2025;9(6):92. 24. Kiani B, Raouf Rahmati A, Bergquist R, Hashtarkhani S, Firouraghi N, Bagheri N, et al. Spatio-temporal epidemiology of the tuberculosis incidence rate in Iran 2008 to 2018. BMC Public Health. 2021;21(1):1093. [ DOI:10.1186/s12889-021-11157-1] [ PMID] [ PMCID] 25. Khazae S, Ayubi E, Mansournia MA, Rafiemanesh H. Trend of some Tuberculosis Indices in Iran during 25 yr Period (1990-2014). Journal of research in health sciences. 2016;16(3):141. 26. Chen Z, Wang T, Du J, Sun L, Wang G, Ni R, et al. Decoding the WHO global tuberculosis report 2024: a critical analysis of global and Chinese key data. Zoonoses. 2025;5(1):999. [ DOI:10.15212/ZOONOSES-2024-0061] 27. Khademi F, Sahebkar A. An updated systematic review and meta-analysis on Mycobacterium tuberculosis antibiotic resistance in Iran (2013-2020). Iranian Journal of Basic Medical Sciences. 2021;24(4):428. 28. Nasiri MJ, Heidary M, Goudarzi H, Tabarsi P. Trends in multidrug-resistant tuberculosis in Tehran, Iran: an analysis of published data. GMS hygiene and infection control. 2019;14:Doc11. 29. Ayoubi S, Farnia P, Farnia P, Ghanavi J, Velayati AA. Prevalence and temporal trends of multidrug-resistant tuberculosis in Iran from 1981 to 2023: a systematic review and meta-analysis. The International Journal of Mycobacteriology. 2024;13(3):320-30. [ DOI:10.4103/ijmy.ijmy_162_24] [ PMID] 30. Daneshi S, Mehni EB, Kamali M, Barfar E, Barahouei FB, Hushmandi K, et al. Prevalence and contributing factors of drug-resistant tuberculosis (DR-TB) in iran: a systematic review. BMC Infectious Diseases. 2025;25(1):1004. [ DOI:10.1186/s12879-025-11439-8] [ PMID] [ PMCID] 31. Moradinazar M, Afshar ZM, Ramazani U, Shakiba M, Shirvani M, Darvishi S. Epidemiological features of tuberculosis in the Middle East and North Africa from 1990 to 2019: results from the global burden of disease Study 2019. African Health Sciences. 2023;23(3):366. [ DOI:10.4314/ahs.v23i3.43] [ PMID] [ PMCID] 32. Bai W, Ameyaw EK. Global, regional and national trends in tuberculosis incidence and main risk factors: a study using data from 2000 to 2021. BMC Public Health. 2024;24(1):12. [ DOI:10.1186/s12889-023-17495-6] [ PMID] [ PMCID] |
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
|
Research code: 403000154 Ethics code: IR.JUMS.REC.1403.109 Clinical trials code: NA
|
|
Open Access Statement: This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium or format, provided that the original work is properly cited.
|
|
|
|
